This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Is Idexx (IDXX) Down 6.6% Since Last Earnings Report?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now
by Zacks Equity Research
Investors are optimistic about IDEXX's (IDXX) strong global performance.
IDEXX (IDXX) Global Sales, Instrument Placement Robust
by Zacks Equity Research
IDEXX (IDXX) continues to demonstrate solid growth globally, primarily aided by a gain in CAG and Water businesses.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Zacks Industry Outlook Highlights Edwards Lifesciences, IDEXX Laboratories and Hologic
by Zacks Equity Research
Edwards Lifesciences, IDEXX Laboratories and Hologic have been highlighted in this Industry Outlook article.
3 Medical Instruments Stocks to Buy Amid Improving Industry Trends
by Urmimala Biswas
The Zacks Medical - Instruments industry is growing on rising demand for digital health. EW, IDXX and HOLX are set to gain the most. Yet, the ongoing inflation, in the form of rising freight, raw material costs, is disrupting the trend.
Are Medical Stocks Lagging IDEXX Laboratories (IDXX) This Year?
by Zacks Equity Research
Here is how Idexx Laboratories (IDXX) and Aeterna Zentaris (AEZS) have performed compared to their sector so far this year.
Should You Invest in the First Trust Water ETF (FIW)?
by Zacks Equity Research
Sector ETF report for FIW
TMO vs. IDXX: Which Stock Is the Better Value Option?
by Zacks Equity Research
TMO vs. IDXX: Which Stock Is the Better Value Option?
Molina Healthcare (MOH) Q4 Earnings Beat on Solid Medicaid Unit
by Zacks Equity Research
Molina Healthcare's (MOH) fourth-quarter results benefit from its strong Medicaid and Medicare businesses. Management expects 2023 adjusted EPS at a minimum of $19.75.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Is AEterna Zentaris (AEZS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Aeterna Zentaris (AEZS) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.
IDEXX (IDXX) Q4 Earnings Beat Estimates, Margins Increases
by Zacks Equity Research
IDEXX's (IDXX) Q4 revenues are driven by continued benefits from expanding the global premium instrument installed base.
DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter results are likely to reflect rising global awareness of its real-time CGM.
Idexx Laboratories (IDXX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 6.77% and 1.48%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Catalent (CTLT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Catalent's (CTLT) Q2 results are likely to have been driven by robust segmental performances.
Here's How Much a $1000 Investment in Idexx Laboratories Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Earnings Preview: Sensus Healthcare, Inc. (SRTS) Q4 Earnings Expected to Decline
by Zacks Equity Research
Sensus Healthcare, Inc. (SRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in the Cards for Mesa Laboratories' (MLAB) Q3 Earnings?
by Zacks Equity Research
Continued strength in Mesa Laboratories' (MLAB) Clinical Genomics segment is expected to have driven up Q3 sales.
The Zacks Analyst Blog Highlights Expedia, IDEXX Laboratories, Tradeweb Markets, SolarEdge Technologies and Sanofi
by Zacks Equity Research
Expedia, IDEXX Laboratories, Tradeweb Markets, SolarEdge Technologies and Sanofi are included in this Analyst Blog.
SONVY or IDXX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SONVY vs. IDXX: Which Stock Is the Better Value Option?
Top 5 Nasdaq Composite Stocks to Buy Ahead of Q4 Earnings
by Nalak Das
Five Nasdaq Composite companies are set to beat earnings estimates. These are: EXPE, IDXX, SNY, TW and SEDG.
HCA Healthcare (HCA) Q4 Earnings Lag on High Costs, Hikes Dividend
by Zacks Equity Research
HCA Healthcare's (HCA) fourth-quarter results suffer a blow from added expenses incurred due to Hurricane Ian. Increased patient admissions partly offset the downside.
Idexx Laboratories (IDXX) Earnings Expected to Grow: What to Know Ahead of Q4 Release
by Zacks Equity Research
Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IDEXX (IDXX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
IDEXX's (IDXX) CAG premium instrument placements are expected to have recorded significant growth in Q4 owing to continued rise in Catalyst and premium hematology placements.